Sulfamylon® For 5 % Topical Solution + Topical Antimicrobial/Antifungal Medications
ApprovedTerminated 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedAbout Sulfamylon® For 5 % Topical Solution + Topical Antimicrobial/Antifungal Medications
Sulfamylon® For 5 % Topical Solution + Topical Antimicrobial/Antifungal Medications is a approved stage product being developed by Viatris for Burns. The current trial status is terminated. This product is registered under clinical trial identifier NCT00634166. Target conditions include Burns.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00634166 | Approved | Terminated |
Competing Products
12 competing products in Burns
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| R-Pdf/Gbb 0.01% gel | Johnson & Johnson | Phase 2 | 52 |
| Ceftolozane/tazobactam | Merck | Approved | 85 |
| linezolid | Pfizer | Phase 1 | 32 |
| Somatropin + 0.09% Saline Solution | Pfizer | Phase 2/3 | 64 |
| Ciprofloxacin (BAYO9867) + Ciprofloxacin (BAYO9867) | Bayer | Phase 3 | 74 |
| cP12 | United Therapeutics | Phase 2 | 49 |
| cNP8 | United Therapeutics | Phase 1 | 30 |
| Sheet skin grafts affixed with Fibrin Sealant (lyophilized) with 4 IU/mL Thrombin | Baxter | Phase 1/2 | 38 |
| I-020502 | Baxter | Phase 2 | 49 |
| Pathogen-Reduced Plasma + Crystalloid Solutions | Cerus | Approved | 77 |
| NexoBrid + Gel Vehicle | MediWound | Phase 3 | 69 |
| NexoBrid | MediWound | Phase 3 | 69 |